Head-to-head evidence
Asenapine vs Lurasidone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Asenapine
Marketed by AbbVie and partners
NCT00212784 · Phase 3 · completed
This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
Lurasidone
Marketed by Sumitomo Pharma
NCT00549718 · Phase 3 · completed
The study randomized approximately 500 participants to lurasidone 40, 80, or 120 mg or placebo and used quadruple masking of participants, clinicians, investigators, and outcome assessors. Its clinical primary endpoint, change in total PANSS score over 6 weeks, favored lurasidone overall versus placebo and was statistically significant (p<0.05).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Lurasidone's landscape